144 related articles for article (PubMed ID: 19065718)
1. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.
Kircher SM; Gurbuxani S; Smith SM
J Gastrointest Cancer; 2007; 38(1):19-23. PubMed ID: 19065718
[TBL] [Abstract][Full Text] [Related]
2. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review.
Kircher SM; Gurbuxani S; Smith SM
J Gastrointest Cancer; 2007; 38(1):59-62. PubMed ID: 19065726
[TBL] [Abstract][Full Text] [Related]
3. [A case of effective use of alemtuzumab in a male patient with T-cell lymphoma].
Sokolov AH; Parovichnikova EN; Isaev VG; Ustinova EN; Shavlokhov VS; Atopkov VA; Model SV; Tsyba NN; Kaplanskaia IB; Kliasova GA; Aleksanian MZh; Vishnevskaia ES; Togonidze DK; Mirzoian EE; Savchenko VG
Ter Arkh; 2004; 76(12):73-5. PubMed ID: 15724932
[No Abstract] [Full Text] [Related]
4. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
[TBL] [Abstract][Full Text] [Related]
5. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; van Marwijk Kooy M; Lugtenburg PJ; van Putten WLJ; Luten M; Oudejans J; van Imhoff GW
Ann Oncol; 2011 Jul; 22(7):1595-1600. PubMed ID: 21212158
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous panniculitis-like T-cell lymphoma with extracutaneous dissemination demonstrated on FDG PET/CT.
Babb A; Zerizer I; Naresh KN; Macdonald D
Am J Hematol; 2011 Apr; 86(4):375-6. PubMed ID: 21442643
[No Abstract] [Full Text] [Related]
7. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
8. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Jaeger G; Bauer F; Brezinschek R; Beham-Schmid C; Mannhalter C; Neumeister P
Ann Oncol; 2008 May; 19(5):1025-6. PubMed ID: 18375525
[No Abstract] [Full Text] [Related]
9. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; Coenen JL; Boers JE; van Imhoff GW; Rosati S
Blood; 2008 Aug; 112(4):1039-41. PubMed ID: 18502831
[TBL] [Abstract][Full Text] [Related]
10. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Weidmann E; Hess G; Chow KU; Krause SW; Subklewe M; Kruse J; Weisel KC; Soekler M; Kim SZ; Napieralski S; Rech J; Dreyling M; Jäger E; Mitrou PS
Leuk Lymphoma; 2010 Mar; 51(3):447-55. PubMed ID: 20141439
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
13. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
[No Abstract] [Full Text] [Related]
14. Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
Phillips EH; Devereux S; Radford J; Mir N; Adedayo T; Clifton-Hadley L; Johnson R
Leuk Lymphoma; 2019 Sep; 60(9):2291-2294. PubMed ID: 30773077
[No Abstract] [Full Text] [Related]
15. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.
Moskowitz CH; Schöder H; Teruya-Feldstein J; Sima C; Iasonos A; Portlock CS; Straus D; Noy A; Palomba ML; O'Connor OA; Horwitz S; Weaver SA; Meikle JL; Filippa DA; Caravelli JF; Hamlin PA; Zelenetz AD
J Clin Oncol; 2010 Apr; 28(11):1896-903. PubMed ID: 20212248
[TBL] [Abstract][Full Text] [Related]
16. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.
Dupuis J; Itti E; Rahmouni A; Hemery F; Gisselbrecht C; Lin C; Copie-Bergman C; Belhadj K; El Gnaoui T; Gaillard I; Kuhnowski F; Meignan M; Haioun C
Ann Oncol; 2009 Mar; 20(3):503-7. PubMed ID: 19074215
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.
Adams HJ; Kwee TC
Crit Rev Oncol Hematol; 2016 Oct; 106():55-63. PubMed ID: 27637352
[TBL] [Abstract][Full Text] [Related]
18. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
19. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
20. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
